Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Pre-exposure prophylaxis (PrEP) is an evidence-based new biomedical HIV prevention
intervention, which involves the pre-emptive use of daily (or event-based) antiretroviral …

Young, Black, gay bisexual or other MSM are significantly less likely to use PrEP than their
White counterparts. These disparities may be due, in part, to medical mistrust and …

Pre-exposure prophylaxis (PrEP) is an effective HIV prevention strategy. Few studies have
explored adolescents and young people's perspectives toward PrEP. We conducted 24 …

With thorough coverage of inequality in health care access and practice, this leading
textbook has been widely acclaimed by teachers as the most accessible of any available. It …

Purpose While the annual rate of new HIV infections and diagnoses has remained stable for
most groups, troubling increases are seen in transgender women and racial/ethnic-minority …

Abstract In May 2018, the US Food and Drug Administration approved daily oral pre-
exposure prophylaxis (PrEP) for adolescents under age 18. Although this is an important …

Despite documented effectiveness of pre-exposure prophylaxis (PrEP), PrEP uptake
remains low among at-risk populations. The 2015 CDC report estimates that about 1.2 …

HIV remains a public health concern in the United States. Although pre-exposure
prophylaxis (PrEP) can be expected to reduce HIV incidence, its uptake, adherence, and …

Background: In the United States, young men who have sex with men (YMSM) of color
represent a high number of new HIV diagnoses annually. HIV pre-exposure prophylaxis …